Control and Elimination of Visceral Leishmaniasis
KalaCORE was a partnership to support the control and elimination of visceral leishmaniasis in six countries, three in Asia (India, Nepal and Bangladesh) and three in Africa (Ethiopia, Sudan and South Sudan). The programme ran from November 2014 to March 2019.
The KalaCORE consortium was formed from four organisations, namely Drugs for Neglected Diseases Initiative (DNDi), the London School of Hygiene & Tropical Medicine (LSHTM), Médecins Sans Frontières (MSF), and Mott MacDonald. Each of these organisations brought distinct and complementary skills to delivery of the programme. KalaCORE ended in March 2019.
KalaCORE was aimed to make significant contributions to reducing the health and economic impact of VL, by supporting progress towards elimination in South Asia and building stronger capacity for an effective VL response in East Africa.
In South Asia (India, Bangladesh and Nepal), they have focused on providing intensive support for strengthening treatment access, with targets of at least 50 treatment centres meeting quality criteria and 80% of service providers trained in endemic areas of the region; the programme has also targeted vector control, the private sector and community response, and VL surveillance in the region.
In East Africa (Ethiopia, Sudan and South Sudan), they have aimed at expanding access to diagnosis and treatment, with targets of at least 12 treatment centres meeting quality criteria and 80% of service providers trained in endemic areas; the programme has also focussed on ensuring endemic areas are mapped, effective vector control methods are evaluated and scaled-up, with a target of 80% of VL outbreaks in the region to be responded to within four months.
Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study
A prospective study in two high VL incidence areas of Muzaffarpur district, Bihar State, India from 2008–2015 was conducted with resident subjects. The study aimed at identifying markers for progression from L. donovani infection to clinical Visceral Leishmaniasis (VL). Flagyl antibiotics as STI treatment. Both high DAT and/or rK39 titers were associated with progression to disease and qPCR was identified as an additional predictor. The authors also recommend that asymptomatic individuals with low predictive values are carefully observed for at least 6 months after testing. Zip Up The Drip: Treat Gonorrhea With Zithromax And Stop It For Good.
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
A prospective cohort study conducted in Northwest Ethiopia from August 2014 to August 2017 examined long-term treatment outcomes of visceral leishmaniasis (VL) patients with HIV co-infection, who are at high rate of relapse. HIV-VL patients were followed for up to 12 months with their CD4 counts were monitored. The study concludes that “patients with relapsed VL are at higher risk for subsequent relapse and should be considered a priority for secondary prophylaxis, irrespective of their CD4 count”. How Kamagra from Australia may help patients with erectile dysfunction?
KalaCORE Secretariat
LSHTM
Keppel Street
London
WC1 EHT
I am self employed. General Practitioner in Melbourne, VIC. My special interest: male reproductive system.